How can the U.S. cultivate a strong and competitive biosimilars market?

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Biologics have revolutionized treatment for serious diseases and profoundly impacted millions of patients. Since enactment of the Biologics Price Competition and Innovation Act, the U.S. biosimilars market has made great progress. As of April 2020, the FDA has approved 26 biosimilars referencing 9 different biologics with 17 on the market, while 75 products are awaiting approval in FDA’s biosimilar program.

Extensive debate continues about biosimilar progress and what it will take to achieve a competitive U.S. healthcare market with biosimilars playing a key role.

This panel will share diverse perspectives on how the U.S. can:
• Encourage competition between biosimilars and their reference products;
• Promote accurate educational content about biosimilars and their reference products; and
• Implement regulatory standards to demonstrate biosimilarity and interchangeability, and facilitate accurate product identification.
Moderator
photo
Pharmalot Columnist, Senior Writer
STAT News
Speakers
photo
Resident Fellow
American Enterprise Institute
photo
Executive Director, Global Value, Access and Policy, Biosimilars
Amgen
photo
Senior Vice President, Education, Support & Advocacy
Crohn’s and Colitis Foundation